In Vivo Partial Reprogramming Reduces Ischemic Brain Damage in Aging Mice

A preclinical study reported that cyclic in vivo Yamanaka-factor expression in aged mice reduces brain damage and demyelination following stroke, suggesting partial reprogramming holds potential as an acute neuroprotective intervention.

Researchers evaluated short-term partial cellular reprogramming through cyclic expression of Yamanaka factors (OSKM) in a Tet-ON aged mouse model (12-18 months old).

To measure brain resilience, the animals underwent permanent middle cerebral artery occlusion (pMCAo) to induce ischemic stroke.

Forty-eight hours post-ischemia, OSKM-induced mice exhibited a significantly smaller damaged cortical area (24.9% versus 31.5% in wild-type controls), improved neurological scores, and superior performance in the tightrope test.

Histological assays showed that partial reprogramming preserved neuronal density in the ischemic cortex and prevented the reactive astrocytic activation (GFAP+) typically observed in wild-type controls.

OSKM induction was shown to occur across major neural cell types, including neurons, astrocytes, microglia, and oligodendrocytes.

The treatment also significantly increased the abundance of total oligodendrocytes (Olig2+) and oligodendrocyte precursor cells (PDGFRα+) post-ischemia, supporting myelin integrity.

Aging is the primary risk factor for stroke, which represents a leading cause of mortality and long-term disability globally.

This study is the first to demonstrate the acute neuroprotective effects of in vivo brain cell reprogramming specifically within aged mammals.

The preservation of myelin-associated glycoprotein (MAG) and recruitment of oligodendrocyte precursor cells suggest that partial reprogramming can actively counter age-related decline in remyelination and repair systems.

The universal expression of induced OSKM factors across neurons and glial cells suggests that systemic or targeted partial reprogramming therapies could act broadly across the entire brain microenvironment.

The findings offer preclinical validation for biotechnology platforms targeting partial epigenetic reprogramming and Yamanaka-factor expression.

Evidence of neuroprotection in an acute ischemic context may encourage clinical-stage developers to expand their pipelines from chronic neurodegenerative indications to acute cerebrovascular conditions.

Demonstrating combined benefits in neuronal survival, astrocytic dampening, and oligodendrocyte-driven myelination positions reprogramming as a potentially superior multi-mechanism alternative to single-target neuroprotective drugs.

Preclinical studies investigating downstream metabolic and molecular pathways, such as cellular transitions from oxidative phosphorylation to glycolysis.

Long-term recovery data evaluating whether the protective benefits of cyclic OSKM induction are maintained weeks or months following the acute phase of ischemic stroke.